[National guidelines for treatment of chronic myelogenous leukemia].
Wisløff
Finn
F
Hematologisk avdeling Medisinsk divisjon Ullevål universitetssykehus 0407 Oslo. f.g.b.wisloff@ioks.uio.no
Brinch
Lorentz
L
Hammerstrøm
Jens
J
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001752:Blast Crisis; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D008875:Middle Aged; D009664:Norway; D017410:Practice Guidelines as Topic; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D033581:Stem Cell Transplantation; D014184:Transplantation, Homologous
D000970:Antineoplastic Agents; D016898:Interferon-alpha; D011505:Protein-Tyrosine Kinases; D006918:Hydroxyurea